The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

By Stefan Blech, T. Ebner, Eva Ludwig-Schwellinger, J. Stangier, W. Roth. Drug Metabolism And Disposition, 2008

732 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery

View Paper: https://www.semanticscholar.org/paper/9f4e9a78eadee060900136cf210ff088acf629fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. A. Goette
2. J. Stangier

In Hematology

1. J. Stangier

In Surgery

1. J. Stangier

Citations in the corpus

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “The concomitant use of PPIs and H2-blockers leads to a small reduction in bioavailability of dabigatran, but without effect on clinical efficacy.(158,159) There is also no relevant antacid interaction for the other NOACs.”
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010, background): “Following oral administration, dabigatran etexilate is rapidly hydrolysed in vivo to the active form, dabigatran (7).”